This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary IL-10 Therapeutic Antibody Development
Background of IL-10
Due to its anti-inflammatory properties and immunomodulatory functions, IL-10 is considered a potential therapeutic target for various tumors, chronic inflammatory, and autoimmune diseases in the treatment of companion animal diseases. BioVenic offers veterinary IL-10 therapeutic antibody development services, covering the entire process from gene synthesis to later-stage validation, aiding in providing potential treatment options for diseases affecting companion animals.
Background of IL-10
| Full Name | Interleukin 10 |
|---|---|
| Aliases | CSIF, GVHDS, IL10, IL10A, TGIF. |
| Target Profile | IL-10 is an anti-inflammatory cytokine, widely present in the immune system, primarily produced by monocytes and to a lesser extent by lymphocytes. It can downregulate the expression of Th1 cytokines, MHC class II antigens, and co-stimulatory molecules on macrophages. Additionally, IL-10 promotes the proliferation of B cells and antibody production, as well as enhancing the activity of specific T cell subgroups, such as regulatory T cells. |
MoA of IL-10
Each monomer of the homodimeric IL-10 substrate molecule binds to an IL-10Rα receptor, leading to the subsequent recruitment of the IL-10Rβ chain, forming a tetrameric complex composed of two heterodimeric IL-10 receptors (IL-10Rα and IL-10Rβ complexes), each complex binding to a monomer of the IL-10 homodimer. It signals downstream through phosphorylation and the formation of JAK-STAT complexes, activating pathways including STAT, PI3K, and MAPK, leading to changes in NF-κB expression.
Fig.1 Schematic diagram of IL-10 signaling pathway.1
Application in Veterinary Therapeutics
In the tumor microenvironment, IL-10 is secreted by cancer cells and various immune cells (including myeloid and lymphoid cell lineages). It can regulate cellular proliferation and metastasis, as well as exert inhibitory effects on other effector immune cells including potent anti-tumor cytotoxic NK and CD8 T cells, enhancing tumor cell survival by controlling anti-tumor immunity. Neutralizing the action of IL-10 using therapeutic antibodies can induce tumor-specific cytotoxic immune responses, offering the potential to inhibit tumor growth, spread, and immune evasion. Additionally, as canines are primary domestic hosts for Leishmania infantum, these parasites might use IL-10 as an evasion mechanism. In these cases, using therapeutic antibodies targeting IL-10 may help enhance the animal's immune response to the pathogen.
Veterinary IL-10 Therapeutic Antibody Development Services
IL-10 is a multifaceted immune-suppressive cytokine with immunoregulatory and angiogenic functions. Considering the therapeutic potential of IL-10 therapeutic antibodies in companion animal cancers and other inflammation-related diseases, BioVenic offers veterinary IL-10 therapeutic antibody development services. We utilize various advanced technologies, including hybridoma, single B cell, and phage display techniques, to assist in the development of veterinary therapeutic antibodies specifically designed to modulate IL-10 activity. Our services extend beyond antibody preparation to include comprehensive antibody characterization, engineering, and species-specific antibody development, ensuring that the veterinary therapeutic antibodies targeting IL-10 achieve the desired therapeutic effects.
For more information about our veterinary IL-10 therapeutic antibody development services, please click the link below.
Why Choose Us?
BioVenic offers customized veterinary therapeutic antibody development services, including tailored antibody design, optimization, and validation to meet specific research targets.
We provide species-specific antibody development services to cater to the unique therapeutic antibody needs of different species, reducing the safety concerns associated with antibody immunogenicity.
We adhere to ethical standards at entire stages of veterinary therapeutic antibody development, ensuring the welfare of animals used throughout the development process.
IL-10 plays a crucial role in various types of companion animal diseases, particularly in certain tumors and inflammatory diseases related to the body's immune response. BioVenic offers veterinary IL-10 therapeutic antibody development services to assist you in providing safer and more effective treatment options for companion animals. If you are considering developing veterinary IL-10 therapeutic antibodies, we invite you to contact us for more information.
Reference
- Rallis, Kathrine S., et al. "IL-10 in cancer: an essential thermostatic regulator between homeostatic immunity and inflammation–a comprehensive review." Future Oncology 18.29 (2022): 3349-3365.